Which has stronger earnings & valuation, KZIA or PROK?

Novogen has higher revenue and earnings than ProKidney. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $1.23M 84.78 -$13.41M N/A N/A ProKidney $890K 533.31 -$68.99M -$0.55 N/A

Is KZIA or PROK more profitable?

Novogen has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A ProKidney -10,288.39% N/A -27.39%

Which has stronger valuation and earnings, AUTL or KZIA?

Novogen has lower revenue, but higher earnings than Autolus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autolus Therapeutics $75.39M 5.72 -$287.53M -$1.06 N/A Novogen $1.23M 84.78 -$13.41M N/A N/A

Which has better earnings & valuation, ARVN or KZIA?

Novogen has lower revenue, but higher earnings than Arvinas. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 1.68 -$80.80M $0.10 68.40 Novogen $1.23M 84.78 -$13.41M N/A N/A

Is ARVN or KZIA more profitable?

Arvinas has a net margin of 2.94% compared to Novogen's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Novogen's return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% Novogen N/A N/A N/A

Which has better earnings & valuation, CAPR or KZIA?

Novogen has lower revenue, but higher earnings than Capricor Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics $22.27M 17.96 -$105.04M -$2.45 N/A Novogen $1.23M 84.78 -$13.41M N/A N/A

Is CAPR or KZIA more profitable?

Novogen's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Novogen N/A N/A N/A

Which has preferable earnings & valuation, KZIA or KMDA?

Kamada has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $1.23M 84.78 -$13.41M N/A N/A Kamada $180.46M 2.45 $20.20M $0.38 20.24

Is KZIA or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Novogen's net margin of 0.00%. Kamada's return on equity of 8.37% beat Novogen's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Kamada 11.60% 8.37% 5.85%

Novogen (KZIA) Competitors

$7.05 -0.99 (-12.36%)

As of 02:31 PM Eastern

Compare

KZIA vs. PROK, AUTL, ARVN, CAPR, and KMDA

Should you buy Novogen stock or one of its competitors? Novogen's main competitors and comparable companies include ProKidney (PROK), Autolus Therapeutics (AUTL), Arvinas (ARVN), Capricor Therapeutics (CAPR), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novogen compare to ProKidney?

Novogen (NASDAQ:KZIA) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Novogen presently has a consensus target price of $28.80, indicating a potential upside of 258.21%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 664.33%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Novogen and Novogen both had 1 articles in the media. Novogen's average media sentiment score of 1.79 equaled ProKidney'saverage media sentiment score.

Company	Overall Sentiment
Novogen	Very Positive
ProKidney	Very Positive

30.9% of Novogen shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novogen has higher revenue and earnings than ProKidney.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$1.23M	84.78	-$13.41M	N/A	N/A
ProKidney	$890K	533.31	-$68.99M	-$0.55	N/A

Novogen has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Novogen has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
ProKidney	-10,288.39%	N/A	-27.39%

Summary

Novogen beats ProKidney on 6 of the 11 factors compared between the two stocks.

How does Novogen compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 1 articles in the media. Novogen's average media sentiment score of 1.79 beat Autolus Therapeutics' score of 0.89 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Novogen	Very Positive

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Autolus Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Novogen has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

Autolus Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 517.28%. Novogen has a consensus price target of $28.80, indicating a potential upside of 258.21%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Novogen has lower revenue, but higher earnings than Autolus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.72	-$287.53M	-$1.06	N/A
Novogen	$1.23M	84.78	-$13.41M	N/A	N/A

Novogen has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Novogen's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Novogen	N/A	N/A	N/A

Summary

Novogen beats Autolus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Novogen compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Arvinas has a net margin of 2.94% compared to Novogen's net margin of 0.00%. Arvinas' return on equity of 1.91% beat Novogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Novogen	N/A	N/A	N/A

In the previous week, Arvinas had 7 more articles in the media than Novogen. MarketBeat recorded 8 mentions for Arvinas and 1 mentions for Novogen. Novogen's average media sentiment score of 1.79 beat Arvinas' score of 0.43 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Arvinas	Neutral
Novogen	Very Positive

Arvinas presently has a consensus target price of $14.55, indicating a potential upside of 112.65%. Novogen has a consensus target price of $28.80, indicating a potential upside of 258.21%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.50
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arvinas has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Novogen has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market.

Novogen has lower revenue, but higher earnings than Arvinas.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.68	-$80.80M	$0.10	68.40
Novogen	$1.23M	84.78	-$13.41M	N/A	N/A

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arvinas beats Novogen on 8 of the 14 factors compared between the two stocks.

How does Novogen compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Capricor Therapeutics currently has a consensus price target of $30.25, indicating a potential upside of 339.68%. Novogen has a consensus price target of $28.80, indicating a potential upside of 258.21%. Given Capricor Therapeutics' higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Novogen's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Novogen	N/A	N/A	N/A

Capricor Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Novogen has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market.

In the previous week, Capricor Therapeutics had 5 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Capricor Therapeutics and 1 mentions for Novogen. Novogen's average media sentiment score of 1.79 beat Capricor Therapeutics' score of 0.47 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Capricor Therapeutics	Neutral
Novogen	Very Positive

Novogen has lower revenue, but higher earnings than Capricor Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	17.96	-$105.04M	-$2.45	N/A
Novogen	$1.23M	84.78	-$13.41M	N/A	N/A

Summary

Novogen beats Capricor Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Novogen compare to Kamada?

Novogen (NASDAQ:KZIA) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Novogen has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market. Comparatively, Kamada has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Kamada has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$1.23M	84.78	-$13.41M	N/A	N/A
Kamada	$180.46M	2.45	$20.20M	$0.38	20.24

30.9% of Novogen shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Novogen's net margin of 0.00%. Kamada's return on equity of 8.37% beat Novogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Kamada	11.60%	8.37%	5.85%

In the previous week, Kamada had 1 more articles in the media than Novogen. MarketBeat recorded 2 mentions for Kamada and 1 mentions for Novogen. Novogen's average media sentiment score of 1.79 beat Kamada's score of 0.40 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Very Positive
Kamada	Neutral

Novogen currently has a consensus target price of $28.80, suggesting a potential upside of 258.21%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 75.55%. Given Novogen's higher probable upside, research analysts clearly believe Novogen is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Novogen on 8 of the 14 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.62M	$3.89B	$7.27B	$12.97B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	N/A	12.96	275.40	25.37
Price / Sales	76.33	1,150.23	562.29	78.82
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-1.36	16.59	10.55	5.95
Net Income	-$13.41M	-$22.65M	$3.50B	$380.75M
7 Day Performance	-22.08%	-6.11%	-3.92%	-3.96%
1 Month Performance	-35.13%	-13.89%	-8.30%	-6.81%
1 Year Performance	3.71%	6.58%	2.35%	-4.58%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	3.5218 of 5 stars	$7.05 -12.4%	$28.80 +308.7%	+18.1%	$94.62M	$1.23M	N/A	6	Positive News Gap Down
PROK ProKidney	1.9909 of 5 stars	$1.59 -0.9%	$12.00 +657.1%	-47.5%	$479.18M	$818K	N/A	231	News Coverage
AUTL Autolus Therapeutics	2.8727 of 5 stars	$1.80 +0.3%	$10.00 +457.1%	-1.8%	$477.76M	$75.39M	N/A	752
ARVN Arvinas	3.2853 of 5 stars	$7.39 +1.1%	$14.55 +96.8%	-30.2%	$475.51M	$262.60M	73.71	246
CAPR Capricor Therapeutics	2.7623 of 5 stars	$7.83 +1.0%	$30.25 +286.3%	+2.4%	$455.35M	$22.27M	N/A	231

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors